Initiation of Sacubitril/Valsartan in Patients with De Novo Heart Failure with Reduced Ejection Fraction: An Analysis of the Transition Study

Background: Initiation of sacubitril/valsartan (S/V) in hospitalised patients with heart failure (HF) with reduced ejection fraction (HFrEF), stabilised after admission due to decompensated HF (ADHF), was associated with superior NT-proBNP reduction compared to enalapril in the PIONEER-HF study. Treatment effect was similar in patients with and without a prior diagnosis of HFrEF.

Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: R. Wachter, S. Michele, K. Witte, E. Straburzynska-Migaj, J. Belohlavek, C. Fonseca, C. Mueller, E. Lonn, W. Bao, A. Noe, H. Schwende, D. Butylin, D. Pascual-Figal, on behalf of TRANSITION investigators Tags: 102 Source Type: research